Mechanistically, formononetin reduces ROS production by regulating Keap1 / Nrf2 signaling pathway, which further reduces ROS-mediated inflammation response, and ultimately inhibits intestinal barrier dysfunction and bacterial translocation to alleviate AP (Fig. 6). The gene discussed is KEAP1; the disease is alkaline phosphatase measurement.